Health technology assessment (HTA) is familiar as technique for gauging the value of specific medical technologies or approaches to care. As Adrian Towse points out, however, HTA has a much broader, ‘macro’ role in contributing to the efficiency of health care systems and supporting universal health coverage. This is particularly crucial in the face of increasing demands and limited budgets.
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Office of Health Economics
OHE’s Paula Lorgelly took part in the Future of Value: Insights from the Experts panel discussion, Indianapolis, on 1 March 2016.
Paula presented a paper which discusses issues with going 'beyond quality adjusted life years (QALYs)' when valuing health care interventions. There are three dimensions to consider when going beyond QALYs: develop a better measure of health (e.g. one that could be condition-specific); use broader measures of benefit; consider a societal perspective (e.g. include productivity loss and carers’ effects).
Paula’s presentation focused on utilising a broader measure of benefit, focusing on alternative such as the capability approach and subjective wellbeing measures.
The panel was sponsored by Eli Lilly.
OHE Lunchtime Seminar with Associate Professor Paula Lorgelly, Deputy Director, Office of Health Economics
From the Antipodes to the Motherland: reflections on HTA decision makers as budget takers and budget makers
High-cost, innovative pharmaceuticals are one serious challenge for health care systems today. At a panel that explored how this might be addressed in Asia, Adrian identified the issues and discussed the potential role of managed entry agreements (MEAs) and performance-based risk-sharing arrangements (PBRSAs). In essence, these measures allow a new medicine to be marketed while additional data about its use in actual clinical practice are being collected. Implementing MEAs or PBSRAs can be difficult, he notes. Crucial to success are assessing local value and ensuring that measures are based on formal written agreements that clealry set out expectations and responsibilities for all stakeholders.
Health technology assessment (HTA) is familiar as technique for gauging the value of specific medical technologies or approaches to care. As Adrian Towse points out, however, HTA has a much broader, ‘macro’ role in contributing to the efficiency of health care systems and supporting universal health coverage. This is particularly crucial in the face of increasing demands and limited budgets.
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Office of Health Economics
OHE’s Paula Lorgelly took part in the Future of Value: Insights from the Experts panel discussion, Indianapolis, on 1 March 2016.
Paula presented a paper which discusses issues with going 'beyond quality adjusted life years (QALYs)' when valuing health care interventions. There are three dimensions to consider when going beyond QALYs: develop a better measure of health (e.g. one that could be condition-specific); use broader measures of benefit; consider a societal perspective (e.g. include productivity loss and carers’ effects).
Paula’s presentation focused on utilising a broader measure of benefit, focusing on alternative such as the capability approach and subjective wellbeing measures.
The panel was sponsored by Eli Lilly.
OHE Lunchtime Seminar with Associate Professor Paula Lorgelly, Deputy Director, Office of Health Economics
From the Antipodes to the Motherland: reflections on HTA decision makers as budget takers and budget makers
High-cost, innovative pharmaceuticals are one serious challenge for health care systems today. At a panel that explored how this might be addressed in Asia, Adrian identified the issues and discussed the potential role of managed entry agreements (MEAs) and performance-based risk-sharing arrangements (PBRSAs). In essence, these measures allow a new medicine to be marketed while additional data about its use in actual clinical practice are being collected. Implementing MEAs or PBSRAs can be difficult, he notes. Crucial to success are assessing local value and ensuring that measures are based on formal written agreements that clealry set out expectations and responsibilities for all stakeholders.
OxfordSM's pharma case studies - providing a call to actionOxfordSM
Brand teams have to be increasingly innovative when finding ways to prompt patients and physicians to intervene at the right time.
Campaigns such as GSK’s Greatest Season Ever for FLONASE®, implemented last year in the United States which made the decision to prepare for the allergy season easier for patients by linking the proactive purchase of the brand to the start of the baseball season.
Providing A Call To Action:
We find that examples from within and outside of healthcare can often prompt this innovation. They act as a way of bringing in new perspectives and allowing teams to explore new avenues and new ideas.
So, in the spirit of hoping this will prompt some new ideas in your brand team, here are our favourite case studies that speak to the need to provide a call to action.
2B Kalfhaus Opportunities and Challenges of Telemedicine EHiN 2014IKT-Norge
Lars Kalfhaus
Country Manager Roche Diabetes Care (ES)
Connect, Engage and Take Decisions
Opportunities and Challenges of Telemedicine Implementation
EHiN 2014, IKT-Norge og HOD
Introduction to the SBRI Competition: Vaccines for Epidemic DiseasesKTN
On Tuesday 12th October 2021, KTN held the event, Introduction to the SBRI Competition: Vaccines for Epidemic Diseases, in partnership with Innovate UK. This event served as a call for applications for the opening of the new SBRI Competition - Vaccines for Epidemic Diseases: Readiness for clinical development and regulatory submission.
https://apply-for-innovation-funding.service.gov.uk/competition/1046/overview
The Role of Health Research Wales in supporting Industry Research in Betsi Cadwaladr University Health Board (BCUHB)
International Clinical Trials Day 20th May 2014
Presented by Rebecca Burns, Health Research Wales, Industry Manager
Pauline Norris (University of Otago, New Zealand): Insight in the New Zealand health care system, with a focus on medicines – current status and developments. Kelan tutkimuksen "Lääke-euro talouden puristuksessa" -seminaari 3.6.2015, Helsinki.
Geneva Pharma Forum on Pharmacovigilance: Partnering for
Patient Safety (Geneva, 20 November 2012), Jeremiah Mwangi, Director, Policy and External Affairs, IAPO
OxfordSM's pharma case studies - providing a call to actionOxfordSM
Brand teams have to be increasingly innovative when finding ways to prompt patients and physicians to intervene at the right time.
Campaigns such as GSK’s Greatest Season Ever for FLONASE®, implemented last year in the United States which made the decision to prepare for the allergy season easier for patients by linking the proactive purchase of the brand to the start of the baseball season.
Providing A Call To Action:
We find that examples from within and outside of healthcare can often prompt this innovation. They act as a way of bringing in new perspectives and allowing teams to explore new avenues and new ideas.
So, in the spirit of hoping this will prompt some new ideas in your brand team, here are our favourite case studies that speak to the need to provide a call to action.
2B Kalfhaus Opportunities and Challenges of Telemedicine EHiN 2014IKT-Norge
Lars Kalfhaus
Country Manager Roche Diabetes Care (ES)
Connect, Engage and Take Decisions
Opportunities and Challenges of Telemedicine Implementation
EHiN 2014, IKT-Norge og HOD
Introduction to the SBRI Competition: Vaccines for Epidemic DiseasesKTN
On Tuesday 12th October 2021, KTN held the event, Introduction to the SBRI Competition: Vaccines for Epidemic Diseases, in partnership with Innovate UK. This event served as a call for applications for the opening of the new SBRI Competition - Vaccines for Epidemic Diseases: Readiness for clinical development and regulatory submission.
https://apply-for-innovation-funding.service.gov.uk/competition/1046/overview
The Role of Health Research Wales in supporting Industry Research in Betsi Cadwaladr University Health Board (BCUHB)
International Clinical Trials Day 20th May 2014
Presented by Rebecca Burns, Health Research Wales, Industry Manager
Pauline Norris (University of Otago, New Zealand): Insight in the New Zealand health care system, with a focus on medicines – current status and developments. Kelan tutkimuksen "Lääke-euro talouden puristuksessa" -seminaari 3.6.2015, Helsinki.
Geneva Pharma Forum on Pharmacovigilance: Partnering for
Patient Safety (Geneva, 20 November 2012), Jeremiah Mwangi, Director, Policy and External Affairs, IAPO
The Life Sciences Advisory Board has refreshed its strategy in order to double the size of the sector in Scotland by 2020. The mission, the vision, the focus but also the strengths of Scotland's Life Sciences field are all presented in this extended strategic report.
EuroBioForum 2013 - Day 1 | Etienne RicherEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Personalised Medicine: A Canadian Collaborative Perspective'
Dr Étienne Richer, Assistant Director at CIHR Institute of Genetics
=======================================
http://www.eurobioforum.eu
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Karen Livingstone - ECO 17: Transforming care through digital healthInnovation Agency
Presentation by Karen Livingstone, Director of Innovation Exchange and SBRI Healthcare, NHS England: Transforming Health and Social Care Services - The Innovation Exchange and SBRI Healthcare at ECO 17: Transforming care through digital health on Tuesday 4 December at Lancaster University, Lancaster
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
Seeking value: Experience from the UK's National Institute for Health and Car...OECD Governance
This presentation was made by Tommy Wilkinson, United-Kingdom, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and a number of recommendations for adapting these systems to respond to the challenges of AMR.
Author(s) and affiliation(s): Margherita Neri (OHE) Grace Hampson (OHE) Christopher Henshall (OHE visiting fellow, independent consultant) Adrian Towse (OHE)
Event: HTAi annual conference 2019
Date: 18/06/2019
Location: Cologne, Germany
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Rachael RitchieEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Genome British Colombia, Canada:
Regional Perspectives on Personalized Medicine in British Columbia, Canada
Dr Rachael Ritchie
Director Business Development Genome British Colombia
=======================================
http://www.eurobioforum.eu
The heart of life sciences full reportEuroBioForum
This report invites you to read more about why Denmark is a unique laboratory for healthcare and welfare
technology, and why Denmark is an excellent place to do business.
EuroBioForum 2013 - Day 2 | Jami TaylorEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# KEYNOTE PRESENTATION #
Personalised medicine education & training
Macro challenges and the path forward
Jami Taylor
Senior Director, Global Access Policy at Janssen, the Pharmaceutical Companies of Johnson & Johnson
Vice-chair of the Education Committee of EPEMED
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Pelagiya DragomirovaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# EARLY BIRD TALK #
The social media & web technology boost - intruder or trigger?
Pelagiya Dragomirova
Communications Advisor at Publimarket
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Frank MolinaEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
EuroBioMed, France:
Private-public collaborations to boost open innovation
Dr Franck Molina
President of EDCA, Chair of diagnosis group of Eurobiomed
Director of Sysdiag
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Mark PoznanskyEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation
Dr Mark Poznansky
President and CEO Ontario Genomics Institute
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 2 | Marc LapageEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Genome Quebec, Canada:
Personalised medicine – Reaching the patient?
Marc LePage
President and CEO Genome Quebec
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# REGIONAL PERSPECTIVES #
Rotterdam Delta, The Netherlands:
What’s keeping medicine from becoming personalised?
Dr Menno Kok,
Advisor Research Strategies Erasmus MC and sector manager Medical Delta
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Pierre MeulienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Canada:
Genomics and personalised health in Canada
Dr Pierre Meulien, President and CEO at Genome Canada
=======================================
http://www.eurobioforum.eu
EuroBioForum 2013 - Day 1 | Oyvind MelienEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Norway:
Personalised medicine in Norway
Dr Øyvind Melien
Senior Advisor at Norwegian Directorate of Health
=======================================
http://www.eurobioforum.eu
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Putting the SPARK into Virtual Training.pptxCynthia Clay
This 60-minute webinar, sponsored by Adobe, was delivered for the Training Mag Network. It explored the five elements of SPARK: Storytelling, Purpose, Action, Relationships, and Kudos. Knowing how to tell a well-structured story is key to building long-term memory. Stating a clear purpose that doesn't take away from the discovery learning process is critical. Ensuring that people move from theory to practical application is imperative. Creating strong social learning is the key to commitment and engagement. Validating and affirming participants' comments is the way to create a positive learning environment.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...BBPMedia1
Grote partijen zijn al een tijdje onderweg met retail media. Ondertussen worden in dit domein ook de kansen zichtbaar voor andere spelers in de markt. Maar met die kansen ontstaan ook vragen: Zelf retail media worden of erop adverteren? In welke fase van de funnel past het en hoe integreer je het in een mediaplan? Wat is nu precies het verschil met marketplaces en Programmatic ads? In dit half uur beslechten we de dilemma's en krijg je antwoorden op wanneer het voor jou tijd is om de volgende stap te zetten.
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Cracking the Workplace Discipline Code Main.pptxWorkforce Group
Cultivating and maintaining discipline within teams is a critical differentiator for successful organisations.
Forward-thinking leaders and business managers understand the impact that discipline has on organisational success. A disciplined workforce operates with clarity, focus, and a shared understanding of expectations, ultimately driving better results, optimising productivity, and facilitating seamless collaboration.
Although discipline is not a one-size-fits-all approach, it can help create a work environment that encourages personal growth and accountability rather than solely relying on punitive measures.
In this deck, you will learn the significance of workplace discipline for organisational success. You’ll also learn
• Four (4) workplace discipline methods you should consider
• The best and most practical approach to implementing workplace discipline.
• Three (3) key tips to maintain a disciplined workplace.
4. Driving Innovation
Challenge Statement
• How to place the UK at the centre of a
new era of stratified medicines:
• Approach: to help accelerate the
development and uptake of treatments
based on the combination of diagnostic
test and drugs
... to benefit the healthcare industry
... to improve patient outcomes
... and for wider UK economic benefit
5. Driving Innovation
Programme Partners
• Technology Strategy Board
• Department of Health
• Scottish Government Health Directorate
• National Institutes for Clinical Excellence
• Medical Research Council
• Cancer Research UK
• Arthritis Research UK
6. Driving Innovation
Stratified Medicine Innovation Platform
Together the partners will invest over £200
million over a 5 year period will be invested
to accelerate Stratified Medicine in the UK.
The aim is to bring the government,
researchers and business together in a
major initiative that will place the UK at the
centre of a revolution in the diagnosis and
treatment of disease.
7. Driving Innovation
First calls
• Tumour Profiling & Data Capture (£5.8m)
– Working along side CRUK programme
– Funded 6 projects
• Inflammatory Biomarkers (£4.3m)
– Working along side MRC:ABPI programme
– Funded 4 projects
• Business Models and Value Systems (£0.9m)
– Funded three projects
8. Driving Innovation
Technology Roadmapping
• Build a UK vision for stratified medicine
– ..... that the UK can deliver
– ...... supported by the SMIP and PMG
• Build a community of people who will help
• Take a strategic view of investment options
– Identify the barriers
– Programme activity to overcome them
– Investments in support of the programme activities
9. Driving Innovation
Vision for 2025
• The UK should be the best place to develop, and have adopted, stratified medicine. This will
benefit patients, provide cost-effective solutions for the NHS and other healthcare providers and
create opportunities for business
• There should be an increased collaborative culture throughout the sector based around shared
resources, and systems should be in place for effective data collection, sharing, governance and
use across sectors (including NHS, business, academia, regulators and NICE)
• It should be quicker and less expensive to develop new drug-diagnostic combinations and have
them licensed, and success should be reflected in increased UK economic growth
• It should be possible for all NHS patients to be involved in medical research if they wish, including
through use of patient information and records, in order to inform the next generation of successful
therapies
• There should be a smooth reimbursement process for stratified therapies and diagnostics, and an
intellectual property (IP) framework that encourages innovation
• The UK health system should have established stratified care pathways, and evidence should be
available to show that patient outcomes are improved where stratified medicine is used
10. Driving Innovation
Key Themes
• Incentivising adoption
• Increasing awareness
• Patient recruitment – consents and ethics
• Clinical trials
• Data – collection, management and use
• Regulation and standards
• Intellectual property
• Bio-banks and biomarkers
• Increasing the impact of R&D investment
11. Driving Innovation
Incentivising adoption
Key message:
Adoption of products into the healthcare
system was seen key during the
workshops.
There are many activities ongoing in this
area reflecting it’s importance to both
Industry and health service
Sound demonstration of value for money
for products is seen as the key
deliverable
12. Driving Innovation
Increasing awareness
Key message:
Need to develop a sound information
base and ensure that professionals
and public are provided with evidence
and a rational for Stratification.
For professionals proof of effectiveness
and value
For public avoid the message that
stratification is a form of rationing
13. Driving Innovation
Patient recruitment – consents and ethics
Key messages:
Often patient consents are restrictive and
do not allow use in research projects
beyond the immediate study. Broader
consents are preferred.
Ethical consideration needs to be given to
later incidental findings particularly in the
area of whole genome screening.
14. Driving Innovation
Clinical trials
Key messages:
Delays around identifying the appropriate
patients and recruiting into trials is one of
the key bottle necks in development.
Any systems to pre-identify patient
cohorts could save significant resource.
New types of trial design will need to be
discussed and approved by regulatory
agencies
15. Driving Innovation
Data – collection, management and use
Key message:
There is a significant quantity of highly
relevant data already in existence within
the NHS and in Pharma companies.
Finding some way to share this data
appropriately could benefit all.
Will require significant effort in data
standardisation to enable open sharing.
16. Driving Innovation
Regulation and standards
Key message:
Regulation is a key gatekeeper in drug
development, all products must be safe
and effective (but how should trials be
designed to show efficacy in preselected
groups)
There was a desire for more regulatory
guidance around both trial design for
stratified products and in the validation of
tests and test protocols.
17. Driving Innovation
Intellectual property
Key message:
This was raised as a concern by diagnostic
companies who were concerned that
“homebrew” tests did not face a level
playing field.
Quality systems being implemented
nationally may help to improve this but
companies would like to see strong IP
protection for tests.
18. Driving Innovation
Bio-banks and biomarkers
Key messages:
There is a recognition that access to
appropriate samples with clinical
annotation is key and that having linked
Bio-banks with standardised systems
would help
Clarity or standardisation around what
information is required to “validate” a
biomarker
19. Driving Innovation
Increasing the impact of R&D investment
Key message:
The desire is to increase the impact of
everyones R&D spend, public, private
and third sector
There was a widespread acceptance that
no single organisation could make a
difference alone. The key is coordinated
activity in multiple areas simultaneously.
Only by working together
20. Driving Innovation
Summary
There was a widespread acceptance that
no single organisation can make a
significant difference working alone. The
key is coordinated activity in multiple
areas simultaneously.
21. Driving Innovation
Where Next?
Adverse Events and Non-Responders
( up to £7.5m)
• Developing tests to predict risk of suffering
adverse events, or non response to
current therapies.
– Phase 1: Health economic valuation of product
and impact on clinical care pathway
– Phase 2: Funding of development of most
successful projects from phase 1
– SBRI in partnership with Dept of Health
22. Driving Innovation
Contact details
• Dr Graham Bell (graham.bell@tsb.gov.uk)
• Dr Alasdair Gaw (alasdair.gaw@tsb.gov.uk)
• https://ktn.innovateuk.org/web/stratified-medicines-
innovation-platform